About Us

Cystic Fibrosis (CF) is one of the most common genetic (inherited) diseases in America. It is also one of the most serious. It mainly affects the lungs and the digestive systems in the body, causing breathing problems and problems digesting foods. It is a chronic disease that currently has no cure. 

The CF Center at Stanford is an integrated disease management program that follows patients from diagnosis through adulthood. 

With the current longer life expectancy for patients with Cystic Fibrosis, our clinic population includes patients of all ages. More than half the patients followed by the Stanford CF Center are adults aged 18 years or older.

Survey Study for any adult CF Patient or Parents of CF Patients

Invitation to Participate in Stanford University Research Survey

Study: Decision-making in Preimplantation Genetic Diagnosis led by Stanford University genetic counseling student Kelly Miller

As you know, families at-risk for cystic fibrosis face challenging circumstances and decisions regarding reproductive options and family planning. Preimplantation genetic diagnosis (PGD), a technique used with in-vitro fertilization to screen embryos and reduce the chance of having a child affected with a genetic condition, is one option for families.

If you are at least 18 years of age and at-risk to pass on cystic fibrosis, you are invited to complete a short, online survey on patient opinions and decision-making regarding PGD. You will be asked to read a brief description of PGD and answer a short series of questions about your opinions and perceptions of this screening (approximately 15 minutes). You do NOT need to have used PGD in order to participate in this study. You will not be asked to give any identifying information in this survey, and all information will be completely anonymous and confidential. If you are interested in participating in this study, please follow the link below. You may only complete this survey once.

You will not be compensated for your participation in this study; however, we would appreciate your input and responses to help us better understand the decisions individuals make regarding preimplantation genetic diagnosis.

Link to Survey: http://tinyurl.com/stanfordgc-pgd

If you have any questions about this study, please contact Kelly Miller at kmiller9@stanford.edu or by phone at 650-724-7190 x1. For participants’ rights questions, contact 1-866-680-2906.




2014 Caregiver of the Year

Dr. Carlos Milla
CF Center Director at
Lucile Packard Children's Hospital Stanford

Dr. Carlos Milla, Director of the Pediatric Cystic Fibrosis Center at Lucile Packard Children’s Hospital Stanford was honored as CFRI's Caregiver of the Year at their spectacular Wine for a Cure event on October 19th. CFRI recognized Dr. Milla for the exceptional care he provides to his patients, his active involvement in CF-related clinical trials, his support of family-centered care in the CF Center, and his expansion of care and support to the Spanish-speaking CF community. Congratulations to Dr. Milla!


Adult Clinic

Adult Clinic

300 Pasteur Drive, 1st Floor, A175

Wednesdays, Thursdays

For New Appointments, call CF Coordinator:


Adult routine appointments

Please call: (650)736-5400

News from the Adult Clinic

Letter from Stanford Adult Team regarding ORKAMBI More 

July 13, 2015

Dear Patient,

As you may already know, Vertex Pharmaceuticals Incorporated has announced that ORKAMBI has been approved by the US Food and Drug Administration.

ORKAMBI is the newest prescription medication used for the treatment of Cystic Fibrosis patients  age 12 years and older and is targeted towards those who have two copies of the F508del mutation in their CFTR gene.  This medication is a combination of Ivacaftor and lumacaftor, and is dispensed in pill form.

The Stanford Adult CF Team is excited about the availability this medication which has shown good promise in decreasing CF exacerbations, and increase in lung function.

We are working now to determine those of our adult patients who qualify to receive ORKAMBI.  We will be happy to discuss this with you at your next clinic visit.

Be advised, if you are eligible for ORKAMBI, you will be required to have a baseline Liver Function test, as well as baseline Spirometry prior to start of drug.  All insurance companies have advised us we will need to submit proof of your genetic mutation, and may in some cases; also require results of your Sweat Chloride. We recognize that for some of you, you may no longer have copies of this, and we are prepared to schedule a repeat Sweat Chloride and/or Genetic Mutation for you if necessary.

Please be patient with us as we work diligently to determine your eligibility for ORKAMBI, and we appreciate your patience as we move forward on this process together.

Best regards,

The Stanford Adult Cystic Fibrosis Team


Pediatric Clinic

Pediatric Clinic

770 Welch Road, Suite 380, 3rd floor

Monday, Tuesday, Wednesday, Friday

For new Pediatric Patients

call: Erica (650)498-2655

Pediatric routine appointments

Please call: (650)724-4788

Bone Density (DEXA) (650)723-6855

PFT (full PFT's) (650) 497-8655

Cystic Fibrosis Research

Research is being conducted on the cause, biological mechanisms, new and better form of therapy and, ultimately, the cure for CF is an important part of our CF Center activities. You can be an important part of that research! 

To find out how, call a research coordinator today!
Phone 650-736-0388 or
email us to join the team!

News Briefs


CF Education Day

March 12th, 2016

Lauren Catron and Dr. Carol Conrad-A Successful Journey to Adult Care

Related Links